Related references
Note: Only part of the references are listed.Racial Differences in the Presentation and Outcomes of Diffuse Large B-Cell Lymphoma in the United States
Pareen J. Shenoy et al.
CANCER (2011)
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia
Jun J. Yang et al.
NATURE GENETICS (2011)
The prognostic value of immunohistochemical subtyping in Chinese patients with de novo diffuse large B-cell lymphoma undergoing CHOP or R-CHOP treatment
Zu-Guang Xia et al.
ANNALS OF HEMATOLOGY (2010)
InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions
Jennifer J. Turner et al.
BLOOD (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
A Decade of Progress in Lymphoma: Advances and Continuing Challenges
Christopher R. Flowers et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development
Lindsay M. Morton et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
William W. L. Choi et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma
Inci Alacacioglu et al.
HEMATOLOGY (2009)
Ethnic Variations in Diagnosis, Treatment, Socioeconomic Status, and Survival in a Large Population-based Cohort of Elderly Patients With Non-Hodgkin Lymphoma
Michael Wang et al.
CANCER (2008)
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
Kai Fu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia
Suat-Cheng Peh et al.
PATHOLOGY INTERNATIONAL (2008)
The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries
Eisuke Shiozawa et al.
LEUKEMIA RESEARCH (2007)
Pro-posed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)
Lindsay M. Morton et al.
BLOOD (2007)
FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Zdravko Mitrovic et al.
HAEMATOLOGICA (2007)
Immune mechanisms in non-Hodgkin lymphoma:: Joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors
Sophia S. Wang et al.
CANCER RESEARCH (2007)
Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph)
Sophia S. Wang et al.
BLOOD (2007)
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma
Dong Hwan Kim et al.
BLOOD (2006)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Changes in cancer registry coding for lymphoma subtypes: Reliability over time and relevance for surveillance and study
CA Clarke et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Lymphorna incidence patterns by WHO subtype in the United States, 1992-2001
LM Morton et al.
BLOOD (2006)
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
LH Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte
P Feugier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
Cancer statistics for African Americans
A Ghafoor et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma
K Itoh et al.
ANNALS OF ONCOLOGY (2000)
Share Paper
